These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38679289)

  • 21. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy.
    Kang J; Cairns J
    BMJ Open; 2022 Jan; 12(1):e055985. PubMed ID: 34992121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals.
    Pennington BM
    Value Health; 2020 Oct; 23(10):1349-1357. PubMed ID: 33032779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making.
    Tai TA; Latimer NR; Benedict Á; Kiss Z; Nikolaou A
    Value Health; 2021 Apr; 24(4):505-512. PubMed ID: 33840428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement.
    Bell Gorrod H; Kearns B; Stevens J; Thokala P; Labeit A; Latimer N; Tyas D; Sowdani A
    Med Decis Making; 2019 Nov; 39(8):899-909. PubMed ID: 31707911
    [No Abstract]   [Full Text] [Related]  

  • 27. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
    Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
    J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
    Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
    Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Hodgson R; Walton M; Biswas M; Mebrahtu T; Woolacott N
    Pharmacoeconomics; 2018 Apr; 36(4):387-398. PubMed ID: 29192397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
    Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
    Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
    Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
    Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Orozco Leal G; Armstrong N; Kernohan A; Ahmadu C; Coughlan D; McDermott K; Duffy S; O'Meara S; Robinson T; Vale L; Kleijnen J
    Pharmacoeconomics; 2023 Jul; 41(7):741-750. PubMed ID: 36952138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups.
    Chauhan D; Miners AH; Fischer AJ
    Int J Technol Assess Health Care; 2007; 23(1):96-100. PubMed ID: 17234022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
    Chen G; Peirce V; Marsh W
    Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. National Institute for Clinical Excellence: NICE works.
    Rawlins MD
    J R Soc Med; 2015 Jun; 108(6):211-9. PubMed ID: 26085559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using automated text classification to explore uncertainty in NICE appraisals for drugs for rare diseases.
    Wiedmann L; Blumenau J; Carroll O; Cairns J
    Int J Technol Assess Health Care; 2024 Jan; 40(1):e5. PubMed ID: 38178720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic Assessment Reviews: is cost-effectiveness analysis helpful or necessary?
    Mistry H; Mason J
    J Health Serv Res Policy; 2018 Oct; 23(4):222-242. PubMed ID: 30309266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE; Witlox W; Wolff R; Chalker A; Hiligsmann M; Wijnen B; Ahmadu C; Ryder S; Armstrong N; Duffy S; Syndikus I; Kleijnen J; Joore MA
    Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
    Simpson EL; Davis S; Thokala P; Breeze PR; Bryden P; Wong R
    Pharmacoeconomics; 2015 Nov; 33(11):1187-94. PubMed ID: 26017401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.